Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

JSP chooses Amneal after ceasing Lannett

Executive Summary

Amneal Pharmaceuticals is to stake a claim in “one of the most compelling generic product markets in the United States today” by signing a 10-year licence and supply agreement with Jerome Stevens Pharmaceuticals (JSP) for levothyroxine sodium tablets, after the family-owned company opted against renewing its existing agreement with Lannett (see page 14).

You may also be interested in...



Amneal Starts Seeking International Partners

In a bid to make better use of Amneal’s US portfolio and pipeline, the company is looking for international licensing partners, especially in Eastern Europe and China, as its new management team looks to restore growth and revive profit margins.

Teva Leapfrogs Taro With Authorized Generic Epiduo Forte Launch

Teva has added another major dermatology brand to its armory, with the launch of an authorized generic version of Galderma’s Epiduo Forte Gel.

Amgen: We Expect To Double Biosimilar Sales By 2030

Amgen management paid close attention to the company’s biosimilar portfolio and pipeline during several recent calls with investors, including what differentiates the firm from its rivals in the biosimilars space.

Topics

UsernamePublicRestriction

Register

GB001094

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel